JP2022538237A5 - - Google Patents
Info
- Publication number
- JP2022538237A5 JP2022538237A5 JP2021576635A JP2021576635A JP2022538237A5 JP 2022538237 A5 JP2022538237 A5 JP 2022538237A5 JP 2021576635 A JP2021576635 A JP 2021576635A JP 2021576635 A JP2021576635 A JP 2021576635A JP 2022538237 A5 JP2022538237 A5 JP 2022538237A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- subject
- pharmaceutical composition
- dose
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025087586A JP2025138634A (ja) | 2019-06-24 | 2025-05-27 | Ｂ細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962865381P | 2019-06-24 | 2019-06-24 | |
| US62/865,381 | 2019-06-24 | ||
| US201962940589P | 2019-11-26 | 2019-11-26 | |
| US62/940,589 | 2019-11-26 | ||
| US202062967401P | 2020-01-29 | 2020-01-29 | |
| US62/967,401 | 2020-01-29 | ||
| US202063034106P | 2020-06-03 | 2020-06-03 | |
| US63/034,106 | 2020-06-03 | ||
| PCT/IB2020/055872 WO2020261093A1 (en) | 2019-06-24 | 2020-06-22 | Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025087586A Division JP2025138634A (ja) | 2019-06-24 | 2025-05-27 | Ｂ細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022538237A JP2022538237A (ja) | 2022-09-01 |
| JP2022538237A5 true JP2022538237A5 (https=) | 2023-06-27 |
Family
ID=71738213
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021576635A Withdrawn JP2022538237A (ja) | 2019-06-24 | 2020-06-22 | Ｂ細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療 |
| JP2025087586A Pending JP2025138634A (ja) | 2019-06-24 | 2025-05-27 | Ｂ細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025087586A Pending JP2025138634A (ja) | 2019-06-24 | 2025-05-27 | Ｂ細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220332821A1 (https=) |
| EP (1) | EP3986569A1 (https=) |
| JP (2) | JP2022538237A (https=) |
| KR (1) | KR20220024729A (https=) |
| CN (2) | CN119679936A (https=) |
| AU (1) | AU2020307471A1 (https=) |
| CA (1) | CA3144324A1 (https=) |
| IL (1) | IL289187A (https=) |
| TW (1) | TW202115114A (https=) |
| WO (1) | WO2020261093A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017001183A2 (pt) | 2014-07-21 | 2017-11-28 | Novartis Ag | tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado |
| US9708412B2 (en) | 2015-05-21 | 2017-07-18 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| EP3493844A4 (en) | 2016-05-20 | 2021-03-24 | Harpoon Therapeutics Inc. | SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| US20200179511A1 (en) * | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| MX2020003915A (es) | 2017-10-13 | 2020-10-08 | Harpoon Therapeutics Inc | Proteinas trispecificas y metodos de uso. |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| US10815311B2 (en) | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
| LT3819007T (lt) | 2019-11-11 | 2024-10-10 | Amgen Research (Munich) Gmbh | Dozavimo režimas, skirtas anti-bcma agentams |
| JP2023524875A (ja) | 2020-05-11 | 2023-06-13 | ヤンセン バイオテツク，インコーポレーテツド | 多発性骨髄腫を治療するための方法 |
| BR112022021956A2 (pt) * | 2020-05-13 | 2022-12-13 | Pfizer | Métodos, terapias e usos para o tratamento de câncer |
| CA3206543A1 (en) * | 2021-01-29 | 2022-08-04 | Shanghai Hansoh Biomedical Co., Ltd. | Antibody-drug conjugate and medical use thereof |
| CN115521381B (zh) * | 2021-06-24 | 2024-10-29 | 益科思特(北京)医药科技发展有限公司 | 结合bcma和cd3的双特异性抗体及其制备方法与应用 |
| WO2023284806A1 (zh) * | 2021-07-14 | 2023-01-19 | 江苏恒瑞医药股份有限公司 | 特异性结合cd38、bcma和cd3的抗原结合分子及其医药用途 |
| CN113908395B (zh) * | 2021-10-13 | 2024-05-17 | 科悦医疗(苏州)有限公司 | 一种促醒仪 |
| MX2024005392A (es) * | 2021-11-03 | 2024-08-06 | Janssen Biotech Inc | Métodos para tratar cánceres y potenciar la eficacia de anticuerpos biespecíficos para bcmaxcd3. |
| CN121712524A (zh) * | 2023-08-18 | 2026-03-20 | 百时美施贵宝公司 | 包含结合bcma和cd3的抗体的组合物以及治疗方法 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| JPH11507538A (ja) | 1995-06-07 | 1999-07-06 | アテナ ニューロサイエンシズ インコーポレイティド | β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ |
| EP1958962A3 (en) | 1997-06-12 | 2013-05-01 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| US7468365B2 (en) | 2000-11-17 | 2008-12-23 | Eli Lilly And Company | Lactam compound |
| GB0120347D0 (en) | 2001-08-21 | 2001-10-17 | Merck Sharp & Dohme | Therapeutic agents |
| KR100838852B1 (ko) | 2003-09-09 | 2008-06-16 | 에프. 호프만-라 로슈 아게 | 감마-세크리테이즈의 활성을 차단하는 말론아미드 유도체 |
| CA2544350A1 (en) | 2003-10-29 | 2005-05-12 | Elan Pharmaceuticals, Inc. | N-substituted benzene sulfonamides |
| ATE535614T1 (de) | 2003-12-30 | 2011-12-15 | Kowa Co | Screening-verfahren fuer gamma-sekretase- inhibitoren |
| DK1730119T3 (da) | 2004-03-23 | 2008-08-11 | Pfizer Prod Inc | Imidazolforbindelser til behandling af neurodegenerative forstyrrelser |
| WO2007019232A2 (en) * | 2005-08-03 | 2007-02-15 | Immunogen, Inc. | Immunoconjugate formulations |
| EP1984321A1 (en) | 2006-02-17 | 2008-10-29 | Wyeth | Methods for preparing sulfonamide substituted alcohols and intermediates thereof |
| EP2011513B1 (en) | 2006-04-25 | 2016-10-19 | The University of Tokyo | Therapeutic agents for alzheimer's disease and cancer |
| WO2009020579A1 (en) | 2007-08-07 | 2009-02-12 | Schering Corporation | Gamma secretase modulators |
| JP5385904B2 (ja) | 2007-08-14 | 2014-01-08 | イーライ リリー アンド カンパニー | γ−セクレターゼ阻害剤 |
| US8084477B2 (en) | 2007-10-31 | 2011-12-27 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |
| TWI530489B (zh) | 2011-03-22 | 2016-04-21 | 必治妥美雅史谷比公司 | 雙（氟烷基）－１，４－苯二氮呯酮化合物 |
| WO2013066740A1 (en) | 2011-10-31 | 2013-05-10 | Merck Sharp & Dohme Corp. | Gamma secretase modulators |
| TWI679212B (zh) * | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| EP2925313A4 (en) | 2012-11-29 | 2016-05-11 | Merck Sharp & Dohme | SPIROCYCLIC SULPHONES AS GAMMA SECRETASE INHIBITORS |
| TW201625692A (zh) * | 2014-11-14 | 2016-07-16 | 諾華公司 | 抗體藥物結合物 |
| EP3223907A2 (en) * | 2014-11-26 | 2017-10-04 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd38 |
| PE20171324A1 (es) * | 2014-11-26 | 2017-09-11 | Xencor Inc | Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales |
| TWI703159B (zh) | 2015-04-13 | 2020-09-01 | 美商輝瑞股份有限公司 | Bcma特異性治療性抗體及其用途 |
| WO2017019496A1 (en) | 2015-07-24 | 2017-02-02 | Berenson James Richard | Gamma secretase modulators for the treatment of immune system dysfunction |
| WO2017136562A2 (en) * | 2016-02-02 | 2017-08-10 | Kadmon Corporation, Llc | Bispecific binding proteins for pd-l1 and kdr |
| JP7267914B2 (ja) * | 2016-11-02 | 2023-05-02 | エンクマフ エスアーエールエル | Ｂｃｍａ及びｃｄ３に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬 |
| US20200179511A1 (en) * | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| KR102870868B1 (ko) * | 2018-06-01 | 2025-10-15 | 노파르티스 아게 | Bcma에 대한 결합 분자 및 이의 용도 |
-
2020
- 2020-06-22 CN CN202411465492.1A patent/CN119679936A/zh active Pending
- 2020-06-22 JP JP2021576635A patent/JP2022538237A/ja not_active Withdrawn
- 2020-06-22 KR KR1020227001880A patent/KR20220024729A/ko not_active Withdrawn
- 2020-06-22 AU AU2020307471A patent/AU2020307471A1/en not_active Abandoned
- 2020-06-22 WO PCT/IB2020/055872 patent/WO2020261093A1/en not_active Ceased
- 2020-06-22 US US17/620,987 patent/US20220332821A1/en active Pending
- 2020-06-22 CA CA3144324A patent/CA3144324A1/en active Pending
- 2020-06-22 EP EP20743802.9A patent/EP3986569A1/en active Pending
- 2020-06-22 TW TW109121083A patent/TW202115114A/zh unknown
- 2020-06-22 CN CN202080059452.0A patent/CN114286828A/zh active Pending
-
2021
- 2021-12-20 IL IL289187A patent/IL289187A/en unknown
-
2025
- 2025-05-27 JP JP2025087586A patent/JP2025138634A/ja active Pending